Fixed dose combination (antiretroviral)

Jump to: navigation, search

Fixed dose combinations of antiretrovirals are multiple antiretroviral drugs combined into a single pill, which helps reduce pill burden. They may combine different classes of antiretrovirals or contain only a single class. Licensed fixed dose combinations are shown in the table below.

Brand Name Drug Names (INN) Date of FDA Approval Company
Combivir® zidovudine + lamivudine September 26, 1997 GlaxoSmithKline
Trizivir® abacavir + zidovudine + lamivudine November 15, 2000 GlaxoSmithKline
Kaletra® lopinavir + ritonavir September 15, 2000 Abbott Laboratories
Epzicom® (in USA)
Kivexa® (in Europe)
abacavir + lamivudine August 2, 2004 GlaxoSmithKline
Truvada® emtricitabine + tenofovir August 2, 2004 Gilead Sciences
Atripla® efavirenz + emtricitabine + tenofovir July 12, 2006 Gilead Sciences and
Bristol-Myers Squibb

See also


Linked-in.jpg